Selected research
Industry Growth & Trends
Global Radiation Toxicity Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Radiation Toxicity Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Radiation Toxicity Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Radiation Toxicity Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Radiation Toxicity Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Radiation Toxicity Therapeutics market include Coherus BioSciences, Jubilant Life Sciences, Mission Pharmacal Company, Partner Therapeutics, Recipharm AB, Siegfried Holdings, Viatris, Amgen and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Radiation Toxicity Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Radiation Toxicity Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Radiation Toxicity Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Radiation Toxicity Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Radiation Toxicity Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Radiation Toxicity Therapeutics Market by Company
Coherus BioSciences
Jubilant Life Sciences
Mission Pharmacal Company
Partner Therapeutics
Recipharm AB
Siegfried Holdings
Viatris
Amgen
Novartis
Radiation Toxicity Therapeutics Segment by Type
Ionizing Radiation
Non-ionizing Radiation
Radiation Toxicity Therapeutics Segment by Application
Hospital
Research & Academic Institutes
Radiation Toxicity Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiation Toxicity Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiation Toxicity Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiation Toxicity Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Radiation Toxicity Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Ionizing Radiation
- Non-ionizing Radiation
Applications
- Hospital
- Research & Academic Institutes
Companies covered
- Coherus BioSciences
- Jubilant Life Sciences
- Mission Pharmacal Company
- Partner Therapeutics
- Recipharm AB
- Siegfried Holdings
- Viatris
- Amgen
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Radiation Toxicity Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Radiation Toxicity Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Radiation Toxicity Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Radiation Toxicity Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Radiation Toxicity Therapeutics Market Size (2021-2032)
- 1.5.1 North America Radiation Toxicity Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Radiation Toxicity Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Radiation Toxicity Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Radiation Toxicity Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Radiation Toxicity Therapeutics Market Size Growth Rate (2021-2032)
2 Radiation Toxicity Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Ionizing Radiation
- 2.1.2 Non-ionizing Radiation
- 2.2 Global Radiation Toxicity Therapeutics Market Size by Type
- 2.2.1 Global Radiation Toxicity Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Radiation Toxicity Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Radiation Toxicity Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Radiation Toxicity Therapeutics Market Size by Regions
- 2.3.1 North America Radiation Toxicity Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Radiation Toxicity Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Radiation Toxicity Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Radiation Toxicity Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Radiation Toxicity Therapeutics Market Size Breakdown by Type (2021-2026)
3 Radiation Toxicity Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Research & Academic Institutes
- 3.2 Global Radiation Toxicity Therapeutics Market Size by Application
- 3.2.1 Global Radiation Toxicity Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Radiation Toxicity Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Radiation Toxicity Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Radiation Toxicity Therapeutics Market Size by Regions
- 3.3.1 North America Radiation Toxicity Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Radiation Toxicity Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Radiation Toxicity Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Radiation Toxicity Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Radiation Toxicity Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Radiation Toxicity Therapeutics Industry Trends
- 4.2 Radiation Toxicity Therapeutics Industry Drivers
- 4.3 Radiation Toxicity Therapeutics Industry Opportunities and Challenges
- 4.4 Radiation Toxicity Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Radiation Toxicity Therapeutics Revenue (2021-2026)
- 5.2 Global Radiation Toxicity Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Radiation Toxicity Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Radiation Toxicity Therapeutics Company, Product Type & Application
- 5.5 Global Radiation Toxicity Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Radiation Toxicity Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Radiation Toxicity Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Radiation Toxicity Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Coherus BioSciences
- 6.1.1 Coherus BioSciences Company Information
- 6.1.2 Coherus BioSciences Business Overview
- 6.1.3 Coherus BioSciences Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Coherus BioSciences Radiation Toxicity Therapeutics Product Portfolio
- 6.1.5 Coherus BioSciences Recent Developments
- 6.2 Jubilant Life Sciences
- 6.2.1 Jubilant Life Sciences Company Information
- 6.2.2 Jubilant Life Sciences Business Overview
- 6.2.3 Jubilant Life Sciences Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Jubilant Life Sciences Radiation Toxicity Therapeutics Product Portfolio
- 6.2.5 Jubilant Life Sciences Recent Developments
- 6.3 Mission Pharmacal Company
- 6.3.1 Mission Pharmacal Company Company Information
- 6.3.2 Mission Pharmacal Company Business Overview
- 6.3.3 Mission Pharmacal Company Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Mission Pharmacal Company Radiation Toxicity Therapeutics Product Portfolio
- 6.3.5 Mission Pharmacal Company Recent Developments
- 6.4 Partner Therapeutics
- 6.4.1 Partner Therapeutics Company Information
- 6.4.2 Partner Therapeutics Business Overview
- 6.4.3 Partner Therapeutics Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Partner Therapeutics Radiation Toxicity Therapeutics Product Portfolio
- 6.4.5 Partner Therapeutics Recent Developments
- 6.5 Recipharm AB
- 6.5.1 Recipharm AB Company Information
- 6.5.2 Recipharm AB Business Overview
- 6.5.3 Recipharm AB Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Recipharm AB Radiation Toxicity Therapeutics Product Portfolio
- 6.5.5 Recipharm AB Recent Developments
- 6.6 Siegfried Holdings
- 6.6.1 Siegfried Holdings Company Information
- 6.6.2 Siegfried Holdings Business Overview
- 6.6.3 Siegfried Holdings Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Siegfried Holdings Radiation Toxicity Therapeutics Product Portfolio
- 6.6.5 Siegfried Holdings Recent Developments
- 6.7 Viatris
- 6.7.1 Viatris Company Information
- 6.7.2 Viatris Business Overview
- 6.7.3 Viatris Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Viatris Radiation Toxicity Therapeutics Product Portfolio
- 6.7.5 Viatris Recent Developments
- 6.8 Amgen
- 6.8.1 Amgen Company Information
- 6.8.2 Amgen Business Overview
- 6.8.3 Amgen Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Amgen Radiation Toxicity Therapeutics Product Portfolio
- 6.8.5 Amgen Recent Developments
- 6.9 Novartis
- 6.9.1 Novartis Company Information
- 6.9.2 Novartis Business Overview
- 6.9.3 Novartis Radiation Toxicity Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Novartis Radiation Toxicity Therapeutics Product Portfolio
- 6.9.5 Novartis Recent Developments
7 North America
- 7.1 North America Radiation Toxicity Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Radiation Toxicity Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Radiation Toxicity Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Radiation Toxicity Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Radiation Toxicity Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Radiation Toxicity Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Radiation Toxicity Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Radiation Toxicity Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Radiation Toxicity Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Radiation Toxicity Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Radiation Toxicity Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Radiation Toxicity Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Radiation Toxicity Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Radiation Toxicity Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Radiation Toxicity Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst